- Home
- RXRX vs NNNN Comparison
RXRX vs NNNN Comparison
Compare RXRX & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- NNNN
- Stock Information
- Founded
- RXRX 2013
- NNNN 2021
- Country
- RXRX United States
- NNNN Germany
- Employees
- RXRX N/A
- NNNN N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RXRX Health Care
- NNNN Health Care
- Exchange
- RXRX Nasdaq
- NNNN Nasdaq
- Market Cap
- RXRX 2.0B
- NNNN 2.2B
- IPO Year
- RXRX 2021
- NNNN 2025
- Fundamental
- Price
- RXRX $6.49
- NNNN $50.62
- Analyst Decision
- RXRX Buy
- NNNN
- Analyst Count
- RXRX 5
- NNNN 0
- Target Price
- RXRX $7.00
- NNNN N/A
- AVG Volume (30 Days)
- RXRX 34.3M
- NNNN 167.4K
- Earning Date
- RXRX 08-07-2025
- NNNN 01-01-0001
- Dividend Yield
- RXRX N/A
- NNNN N/A
- EPS Growth
- RXRX N/A
- NNNN N/A
- EPS
- RXRX N/A
- NNNN 0.06
- Revenue
- RXRX $59,790,000.00
- NNNN $8,185,146.00
- Revenue This Year
- RXRX $23.85
- NNNN N/A
- Revenue Next Year
- RXRX $43.06
- NNNN N/A
- P/E Ratio
- RXRX N/A
- NNNN $936.33
- Revenue Growth
- RXRX 29.32
- NNNN 21.95
- 52 Week Low
- RXRX $3.79
- NNNN $5.18
- 52 Week High
- RXRX $12.36
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- RXRX 66.22
- NNNN N/A
- Support Level
- RXRX $5.13
- NNNN N/A
- Resistance Level
- RXRX $7.14
- NNNN N/A
- Average True Range (ATR)
- RXRX 0.49
- NNNN 0.00
- MACD
- RXRX 0.10
- NNNN 0.00
- Stochastic Oscillator
- RXRX 69.30
- NNNN 0.00
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.